Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phase III Trial Oversight Should Rely On Adverse Event "Summaries," CRO Association Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The Association of Clinical Research Organizations supports using partially blinded data summaries to help institutional review boards overseeing multi-center trials

You may also be interested in...

Adverse Events Definition Should Be Narrower, IRB Groups Tell FDA

The Consortium of Independent Review Boards favors reporting only adverse events that "probably or definitely" related to the study drug. Current regulation requires adverse events to be reported to IRBs if they are "at least possibly" related to the drug.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts